These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 19470958)

  • 1. The scientific and clinical basis for the treatment of Parkinson disease (2009).
    Olanow CW; Stern MB; Sethi K
    Neurology; 2009 May; 72(21 Suppl 4):S1-136. PubMed ID: 19470958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatments for Parkinson disease--past achievements and current clinical needs.
    Poewe W
    Neurology; 2009 Feb; 72(7 Suppl):S65-73. PubMed ID: 19221317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beating a dead horse: dopamine and Parkinson disease.
    Ahlskog JE
    Neurology; 2007 Oct; 69(17):1701-11. PubMed ID: 17954785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
    Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why have we failed to achieve neuroprotection in Parkinson's disease?
    Olanow CW; Kieburtz K; Schapira AH
    Ann Neurol; 2008 Dec; 64 Suppl 2():S101-10. PubMed ID: 19127580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Motor complications in Parkinson disease: clinical manifestations and management.
    Bhidayasiri R; Truong DD
    J Neurol Sci; 2008 Mar; 266(1-2):204-15. PubMed ID: 17897677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can we achieve neuroprotection with currently available anti-parkinsonian interventions?
    Olanow CW
    Neurology; 2009 Feb; 72(7 Suppl):S59-64. PubMed ID: 19221316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship of Parkinson disease with aging.
    Levy G
    Arch Neurol; 2007 Sep; 64(9):1242-6. PubMed ID: 17846263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine agonist-based strategies in the treatment of Parkinson's disease.
    Antonini A; Barone P
    Neurol Sci; 2008 Dec; 29 Suppl 5():S371-4. PubMed ID: 19381765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The patient with Parkinson's disease: part I-treating the motor symptoms; part II-treating the nonmotor symptoms.
    Snyder CH; Adler CH
    J Am Acad Nurse Pract; 2007 Apr; 19(4):179-97. PubMed ID: 17430539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What's in the pipeline for the treatment of Parkinson's disease?
    Sommer DB; Stacy MA
    Expert Rev Neurother; 2008 Dec; 8(12):1829-39. PubMed ID: 19086879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.
    Stoner SC; Dahmen MM; Makos M; Lea JW; Carver LJ; Rasu RS
    Ann Pharmacother; 2009 Sep; 43(9):1426-32. PubMed ID: 19690226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopaminergic transplantation for Parkinson's disease: current status and future prospects.
    Olanow CW; Kordower JH; Lang AE; Obeso JA
    Ann Neurol; 2009 Nov; 66(5):591-6. PubMed ID: 19938101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Parkinson's disease in Thailand: review of the literature and practical recommendations.
    Bhidayasiri R; Ling H
    J Med Assoc Thai; 2009 Jan; 92(1):142-54. PubMed ID: 19260256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidisciplinary care for patients with Parkinson's disease.
    van der Marck MA; Kalf JG; Sturkenboom IH; Nijkrake MJ; Munneke M; Bloem BR
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S219-23. PubMed ID: 20082995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms compensating for dopamine loss in early Parkinson disease.
    Brotchie J; Fitzer-Attas C
    Neurology; 2009 Feb; 72(7 Suppl):S32-8. PubMed ID: 19221312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotection in Parkinson disease.
    Simpkins N; Jankovic J
    Arch Intern Med; 2003 Jul; 163(14):1650-4. PubMed ID: 12885679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo gene delivery for development of mammalian models for Parkinson's disease.
    Ulusoy A; Bjorklund T; Hermening S; Kirik D
    Exp Neurol; 2008 Jan; 209(1):89-100. PubMed ID: 18028909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
    Suchowersky O; Gronseth G; Perlmutter J; Reich S; Zesiewicz T; Weiner WJ;
    Neurology; 2006 Apr; 66(7):976-82. PubMed ID: 16606908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical therapy in Parkinson's disease: evolution and future challenges.
    Keus SH; Munneke M; Nijkrake MJ; Kwakkel G; Bloem BR
    Mov Disord; 2009 Jan; 24(1):1-14. PubMed ID: 18946880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.